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Equal access to colorectal cancer screening 
Population-based screening is eﬀ ective in reducing the 
burden of colorectal cancer, and organised screening 
programmes have been implemented in many European 
countries.1 Maximum participation in screening is crucial 
to achieve the greatest health beneﬁ ts at population 
level. As with most cancer screening programmes, 
however, there is a gradient in uptake of colorectal 
cancer screening by socioeconomic status, from 
the most to the least deprived.2–4 Because colorectal 
cancer screening results in earlier diagnosis or primary 
prevention, inequalities in colorectal cancer outcomes 
between socioeconomic groups are expected to increase 
with wider implementation of screening programmes.5
The data on inequality in colorectal cancer screening 
are predominantly from the USA.4 For Europe, analyses 
from the UK National Health Service Bowel Cancer 
Screening Programme, in which faecal occult blood 
testing is oﬀ ered to individuals aged 60–74 years at 
no cost, have shown uptake of 35% in the lowest 
socioeconomic quintile compared with more than 60% 
in the highest quintile.3 In The Lancet, Jane Wardle and 
colleagues6 present the results of the ASCEND project, 
which involved various mailed interventions aimed at 
lessening socioeconomic inequality for participation 
in the Bowel Cancer Screening Programme in England. 
Wardle and colleagues did four cluster-randomised 
controlled trials in which eligible individuals received 
either standard information about the screening 
programme or supplemented information in diﬀ erent 
forms—a leaﬂ et re-presenting the information in 
important to have adequate numbers of well trained 
and supervised staﬀ  with access to essential therapies 
and investigations; guidelines cannot compensate for 
weak health systems. Addressing issues in quality of care 
and supporting health systems is necessary to tackle the 
challenges of paediatric care in resource-limited settings 
in the era of the Sustainable Development Goals.
The WHO Hospital Care for Children guidelines, which 
includes the ETAT guidelines, are available in print8 in 
many languages and in a new app (iOS and Android) 
that can be updated as new evidence becomes available 
and guidelines change.14 There is, of course, still a 
need for simple guidelines for common conditions. 
The historical principles of WHO guidelines that are ﬁ t 
for context and based on the best available evidence, 
using where possible the minimum number of highly 
predictive clinical signs or laboratory tests, all remain 
relevant. The new ETAT guidelines will need to be 
evaluated, and the design of such research should reﬂ ect 
the broader context and recognise that these are not 
isolated simple interventions. 
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a simpliﬁ ed format; a leaﬂ et describing people’s 
experiences of screening and outcomes; a letter with 
a banner showing the individual’s general practice 
endorsement of the screening programme; or an 
enhanced reminder letter reiterating the screening oﬀ er. 
676 391 recipients were included.
Neither leaﬂ et was associated with any eﬀ ect on 
socioeconomic gradient of uptake of screening or on 
overall uptake. The endorsement letter did not aﬀ ect 
the socioeconomic gradient but was associated with 
increased overall uptake (adjusted odds ratio [OR] 1·07, 
95% CI 1·04–1·10). The enhanced reminder letter showed 
a signiﬁ cant interaction with socioeconomic status 
gradient (p=0·005), with a stronger, albeit small, eﬀ ect 
in the most deprived quintile (adjusted OR 1·11, 95% CI 
1·04–1·20) than in the least deprived (1·00, 0·94–1·06), 
and overall uptake was also increased (1·07, 1·03–1·11). 
Regrettably, therefore, the laudable eﬀ orts to make the 
screening invitation more understandable for people 
from lower socioeconomic groups had little eﬀ ect, 
despite earlier evidence supporting general practice 
endorsement reminder enhancement.7
Where to go from here is unclear. The study illustrates 
the challenges of reducing inequalities in screening uptake 
through written strategies alone, even when based on 
theory and practice. Thus, a uniform mailed screening 
invitation inevitably implies unequal chances of optimum 
colorectal cancer screening outcomes. This issue needs 
consideration because the aim of a population-based 
colorectal cancer screening programme is beyond equal 
participation. Rather, it is to oﬀ er an equal chance of 
optimum colorectal cancer outcomes to everyone.
Providing equitable preventive care implies the use 
of equal screening invitation strategies in situations of 
equal information needs (horizontal equity).8 However, 
that screening invitation strategy might need to diﬀ er 
between subpopulations to achieve equal chances of 
optimum outcomes (vertical equity) is also implied.8 This 
theory suggests that diﬀ erent invitation strategies would 
be needed to provide people from all socioeconomic 
groups with equal chances of beneﬁ ting from the 
screening oﬀ er. The only alternative option is to accept 
socioeconomic inequality in colorectal cancer screening. 
Strategies to increase awareness of the importance 
of screening in local communities, for example via 
general practitioners or telephone support in a variety of 
languages, might be options worth considering.
The second issue that needs to be addressed is related 
to the factual aim of the screening invitation. Colorectal 
cancer screening has potential side-eﬀ ects, including 
potential harm, associated with follow-up colonoscopy. 
The importance of disclosing appropriate information to 
enable target groups to make informed decisions about 
participation has been emphasised.9 Achieving this goal, 
however, is challenging because of the complexity of 
cancer screening programmes.1 Wardle and colleagues6 
did not assess the decision-making process, although it 
seems unlikely that the small eﬀ ect associated with the 
enhanced reminder strategy represents an increase in 
informed participation. That informed non-participation 
could explain the lack of increased participation in the 
trials of additional information leaﬂ ets seems equally 
unlikely. Nevertheless, if the generally lower participation 
among groups with low socioeconomic status was proved 
to be based on informed autonomous choices to not 
participate, attempts to reduce the socioeconomic uptake 
gradient might be undesirable or even immoral. The 
question at stake is how to promote informed decision 
making about cancer screening participation eﬀ ectively, 
especially in groups with low socioeconomic status.
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Faecal occult blood test
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Isavuconazole: a role for the newest broad-spectrum triazole
Invasive mould infection is a serious complication of 
treatment for acute leukaemia and transplantation 
and is increasingly identiﬁ ed with other underlying 
disorders.1,2 In The Lancet, Johan Maertens and colleagues3 
report a randomised, double-blind, non-inferiority study 
comparing a new broad-spectrum triazole, isavuconazole, 
with the current standard treatment, voriconazole, 
in 516 adult patients with suspected invasive mould 
infection. Isavuconazole was non-inferior to voriconazole 
by the primary endpoint of all-cause mortality at day 42 
(19% [48 patients] in the isavuconazole group vs 20% 
[52 patients] in the voriconazole group) in an intention-
to-treat population. The predeﬁ ned 10% non-inferiority 
margin was met by an adjusted treatment diﬀ erence 
in mortality of –1·0% (95% CI −7·8 to 5·7). Mortality is a 
more rigorous endpoint than overall response, which 
relies on interpretation of radiological ﬁ ndings that 
might lag behind clinical improvement.4 Fewer drug-
related adverse events were reported with isavuconazole 
(109 [42%] patients) than with voriconazole (155 [60%] 
patients), particularly those aﬀ ecting eye, hepatobiliary 
system, and skin.3
Will isavuconazole now replace voriconazole as standard 
of care for the treatment of invasive aspergillosis? 
Advantages of isavuconazole over voriconazole include 
its broader spectrum of activity (including most 
mucormycetes), once-daily dosing after the loading dose, 
linear pharmacokinetics, and less interpatient variability in 
exposure, water solubility (thus no need for cyclodextrin 
in the intravenous formulation), and ﬁ nally fewer CYP 
enzyme-mediated drug–drug interactions.5 Isavuconazole 
is cleared by, and is a moderate inhibitor of, CYP3A4. 
Exposure is not aﬀ ected by CYP2C9 or CYP2C19 genotype 
or drug interactions.5 This factor is an advantage, although 
clinicians have learnt to manage voriconazole side-
eﬀ ects, drug interactions, concentrations, and CYP2C19 
genotypes in clinical practice.6
Maertens and colleagues’ study does have some 
limitations. Most patients were undergoing treatment 
for haematological malignant disease and none 
were receiving mould-active triazole prophylaxis. 
The eﬀ ectiveness of isavuconazole treatment after 
mould-active triazole prophylaxis, a common practice 
in patients at risk for mould infection, remains to be 
clariﬁ ed. Further, few patients had mould infections 
other than aspergillosis, with more than 80% of 
mycologically documented infection in both groups 
being Aspergillus aﬀ ecting the respiratory tract.3 The 
eﬀ ectiveness of isavuconazole against moulds other 
than aspergillus and infections involving sanctuary sites 
such as the eye and central nervous system requires 
further evaluation.
Although Maertens and colleagues3 reported mean 
isavuconazole trough plasma concentrations at day 
14 of 3354 ng/mL (SD 1816 ng/mL), similar to those in 
healthy volunteers,5 experience in a more varied patient 
population, including those with gastrointestinal 
tract disturbances (eg, graft versus host disease, 
neutropenic enterocolitis, vomiting, diarrhoea, and 
nasogastric feeding), will be required to be certain that 
therapeutic drug monitoring is unnecessary. Although 
initial recommendations were that therapeutic drug 
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